Kailera's oral weight loss pill met its trial goal, but nausea hit 70% of patients

Kailera stock dropped 10% after Phase 3 data showed roughly 70% of patients on HRS-7535 experienced nausea

SOPA Images / Getty Images

Shares of Kailera Therapeutics fell 10% on Tuesday, a decline triggered by late-stage trial results showing that its oral weight loss drug produced high rates of nausea and vomiting despite successfully reducing body weight. The Waltham, Massachusetts-based biotechnology company announced topline results from two Phase 3 trials of HRS-7535, a once-daily oral drug developed by China's Jiangsu Hengrui Pharmaceutical and licensed to Kailera.

In the obesity trial, called........

© Quartz